BACKGROUND The role of biologic therapies in the treatment of rheumatoid arthritis has expanded, but dosing patterns in the first versus subsequent lines of therapy have not been thoroughly explored. METHODS In order to describe patterns of biologic agent utilization among patients with rheumatoid arthritis, health care claims data on use of abatacept, rituximab, or the anti-tumor necrosis fa...

Methanol extract from aerial parts of Sideritis libanotica Labill. subsp. linearis (Bentham) Borm. were investigated for its in vitro antiproliferative activities against Vero, HeLa and C6 cells. The tests were carried out as dose-dependent assay starting from 25 μg/mL to 250 μg/mL. The extract found to be active against African green monkey kidney (Vero), human uterus carcinoma (HeLa) and Rat ...

BACKGROUND The aim of this study was to evaluate the effect of doubling the starting dose of gonadotrophins on the ovarian response in IVF patients with a low antral follicle count (AFC). METHODS Fifty-two patients with an AFC of <5 follicles of 2-5 mm diameter before starting their first IVF cycle participated in this randomized controlled trial. They were randomized by opening a sealed enve...

AIMS To identify factors associated with glucose control, as measured by HbA1c over 4 years, in people with type 2 diabetes starting insulin therapy. METHODS CREDIT, an observational cohort study, collected data semi-annually over 4 years, on people with type 2 diabetes starting any insulin, in 311 centres in 12 countries; 2803 people had data on HbA1c during follow-up. Multivariable backward...

Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted drug combinations, we identified clinical trials in adult oncology patients who received targeted drug doublets (PubMed, January 1, 2010 through Dec...

OBJECTIVE To evaluate the short- and long-term adverse effects of systemic glucocorticosteroid (GS) therapy in infants with hemangiomas. DESIGN Retrospective chart review of infants treated with GSs for hemangiomas during a 3-year period. SETTING Tertiary care children's hospital. PATIENTS Of 141 patients identified with hemangiomas, 22 were treated with GSs. INTERVENTIONS Minimum of 1-...